- Development of oncolytic HSV-1
-
Generation of genetic modified oncolytic HSV-1 without damage to normal cell
- Improvement of anti-tumor immune response using oncolytic HSV-1
-
Enhancement of anti-tumor immune response by cytokine or immune checkpoint inhibitor expressing oncolytic HSV-1
- Cancer cell-specific targeted oncolytic HSV-1
-
Cancer cell-specific infection and replication by modulation of glycoprotein of HSV-1